- Home
- BEAM vs CGON Comparison
BEAM vs CGON Comparison
Compare BEAM & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAM
- CGON
- Stock Information
- Founded
- BEAM 2017
- CGON 2010
- Country
- BEAM United States
- CGON United States
- Employees
- BEAM N/A
- CGON N/A
- Industry
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- CGON
- Sector
- BEAM Health Care
- CGON
- Exchange
- BEAM Nasdaq
- CGON NYSE
- Market Cap
- BEAM 2.3B
- CGON 2.3B
- IPO Year
- BEAM 2020
- CGON 2024
- Fundamental
- Price
- BEAM $30.43
- CGON $27.85
- Analyst Decision
- BEAM Buy
- CGON Strong Buy
- Analyst Count
- BEAM 10
- CGON 10
- Target Price
- BEAM $48.75
- CGON $65.11
- AVG Volume (30 Days)
- BEAM 1.2M
- CGON 430.1K
- Earning Date
- BEAM 03-04-2025
- CGON 03-04-2025
- Dividend Yield
- BEAM N/A
- CGON N/A
- EPS Growth
- BEAM N/A
- CGON N/A
- EPS
- BEAM N/A
- CGON N/A
- Revenue
- BEAM $349,643,000.00
- CGON $684,000.00
- Revenue This Year
- BEAM N/A
- CGON $158.34
- Revenue Next Year
- BEAM $14.62
- CGON N/A
- P/E Ratio
- BEAM N/A
- CGON N/A
- Revenue Growth
- BEAM 328.73
- CGON 258.12
- 52 Week Low
- BEAM $20.84
- CGON $25.77
- 52 Week High
- BEAM $49.50
- CGON $47.78
- Technical
- Relative Strength Index (RSI)
- BEAM 57.12
- CGON 41.49
- Support Level
- BEAM $25.35
- CGON $27.10
- Resistance Level
- BEAM $35.25
- CGON $29.42
- Average True Range (ATR)
- BEAM 2.10
- CGON 1.15
- MACD
- BEAM 0.56
- CGON -0.10
- Stochastic Oscillator
- BEAM 55.88
- CGON 29.02
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.